Navigation Links
Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
Date:8/23/2007

FDA Approved Product Will Accelerate Growth of Pain Franchise

FRAZER, Pa., Aug. 23 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today it has signed an agreement to acquire the North American rights to AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules) from ECR Pharmaceuticals, a privately held company. Two dosage strengths of AMRIX (15 mg and 30 mg) were approved in February 2007 by the U.S. Food and Drug Administration (FDA) for short-term use as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. The product is not yet available commercially in the United States; however, Cephalon expects to launch the product early in the fourth quarter.

Under the agreement, which is expected to close on or about August 28, 2007, Cephalon will acquire the rights to AMRIX for $100 million cash. The company also could make future cash payments to ECR upon the achievement of certain cumulative net sales milestones. The company anticipates that the transaction will be modestly dilutive in the fourth quarter due to product launch costs; despite this, the company is reaffirming its existing 2007 sales and adjusted income per common share guidance. The transaction is expected to be accretive in 2008 and thereafter.

"AMRIX is an excellent strategic fit with our current sales organization, providing us with a second product that is complementary to many pain relievers used today," said Robert Roche, Executive Vice President, Worldwide Pharmaceutical Operations. "Cyclobenzaprine HCl is the most widely prescribed muscle relaxant in the United States, representing 37 percent of the 45 million prescriptions for muscle relaxants written in 2006, according to IMS. AMRIX has convenient once-daily dosing and a side effect profile that includes very low rates of sedation which will provide physicians and patients an attractive alternative to current therapies.
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... GLOBAL MARKETS , that the global market RNA interference ... nearly $38.8 billion by 2018, with a five-year compound ... category, the fastest moving segment of the market, is ... of RNAi therapeutics has shown tremendous growth and has ...
(Date:8/1/2014)... Aug. 1, 2014 Glencoe Software, ... of "Data InPress" ( http://glencoesoftware.com/data-inpress.html ), a ... multidimensional image data into on-line publications.  The ... Video Injection Service. Photo - ... http://photos.prnewswire.com/prnh/20140731/132409 The DataViewer ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Food ... are increasingly searching for food alternatives that offer ... benefits. The food ingredient market has numerous players ... such as Vital Force Technology (VFT). VFT ... than 4,000 energetic patterns, all tested to produce ...
(Date:7/31/2014)... , the leading life sciences employment and news website, launched the ... Illinois , Indiana , ... , Minnesota , Missouri , ... Wisconsin . BioMidwest is a leader in biotech and ... in this region in 2013. The life sciences sector in this area ...
Breaking Biology Technology:Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3Glencoe Software Launches Data InPress 2Glencoe Software Launches Data InPress 3Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2Midwest Biotech Leaders Featured On BioSpace Map 2
... To validate any RNAi experiment, target mRNA , ... using a positive control siRNA that is known to be effective, , ... , Validation is also necessary ... effectiveness and potency of any siRNA sequence. Finally, , ...
... Microarrays , ... engineered to maximize yields of full-length cDNA , ... 100 ng of input RNA in a single round for GeneChip , ... cRNA synthesis powered by , MEGAscript, the best ...
... Total RNA Isolation from Formalin Fixed Paraffin Embedded (FFPE) Tissues , ... Phenol-free isolation of total RNA from , FFPE tissues , ... href="http://www.ambiondx.com/products/optimum/index.html">Optimum , ... and rapid protocol , for ...
Cached Biology Technology:Confirming RNAi Effects Is Now Easier Than Ever 2Confirming RNAi Effects Is Now Easier Than Ever 3Confirming RNAi Effects Is Now Easier Than Ever 4Confirming RNAi Effects Is Now Easier Than Ever 5Improving RNA Amplification 2Improving RNA Amplification 3Improving RNA Amplification 4Improving RNA Amplification 5Improving RNA Amplification 6Improving RNA Amplification 7Improving RNA Amplification 8Improving RNA Amplification 9Improving RNA Amplification 10Improving RNA Amplification 11Improving RNA Amplification 12Improving RNA Amplification 13Improving RNA Amplification 14Optimum FFPE RNA Isolation Kit 2Optimum FFPE RNA Isolation Kit 3Optimum FFPE RNA Isolation Kit 4
(Date:7/31/2014)... protected 100 percent of animal models against the highly ... causes an intestinal disease that kills approximately 30,000 Americans ... Infection and Immunity . , In the ... against the purified toxins produced by C. difficile ... a laboratory model that mimics the human disease, after ...
(Date:7/31/2014)... better identify and treat those with fibromuscular dysplasia (FMD). ... sized arteries in the body, which can restrict blood flow ... new report appearing in August 2014 issue of ... FMD may not be limited to the arteries as currently ... bones and joints, as well as evidence that inflammation may ...
(Date:7/31/2014)... they are an iconic symbol of tropical resorts ... landscape. Some, like Hawaii,s State Flower- Hibiscus ... relatively few botanists and Hawaiian conservation workers, however, ... related group of plants known as Hibiscadelphus ... Hibiscus species are in fact highly endangered. Until ...
Breaking Biology News(10 mins):C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2Brother of Hibiscus is found alive and well on Maui 2
... developed a slow-release anesthetic drug-delivery system that could ... surgery, and may also have a large impact ... used specially designed fat-based particles called liposomes to ... local anesthesia in rats without apparent toxicity to ...
... Climate change will cause some of Australia,s potential weeds to ... by scientists at CSIRO,s Climate Adaptation Flagship. Weeds cost ... or lost production and cause serious damage to the environment. ... GREENHOUSE 09 conference on climate change, CSIRO researcher, Dr John ...
... Fast food and soft drinks may be making children fatter ... tackling childhood obesity, by reducing children,s consumption of unhealthy food ... also actively seek to keep children happy in other ways, ... Professor Rodolfo Nayga from the University of Arkansas in the ...
Cached Biology News:Long-lasting nerve block could change pain management 2Climate change may wake up 'sleeper' weeds 2Eat, drink and be merry? 2
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
... the premium quality siRNAs you need for ... be readily ordered online by providing either ... providing the sense and antisense siRNA sequences. ... Validated and Silencer Pre-designed siRNAs, ...
GEL FILTRATION CAL KIT HMW, 1 EA. *Category: Gel Filtration Gels....
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Biology Products: